Morinaga Milk Industry Co., Ltd. Recognized for Child Nutrition and Community Well-Being Initiative at Asia Responsible Enterprise Awards 2026
KUALA LUMPUR, Malaysia, July 9, 2026 /PRNewswire/ -- Morinaga Milk Industry Co., Ltd. has been recognized under the Social Empowerment category at the Asia Responsible Enterprise Awards (AREA) 2026, organized by Enterprise Asia, with PR Newswire as the Official News Release Distribution Partner. The recognition honors Morinaga Milk's long-term commitment to improving child nutrition and community well-being through...
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden the development path for HCB101, its lead oncology asset, through a new partnership with InxMed....
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The strong financial performance was primarily propelled by sustained revenue growth alongside systematic improvements of operational efficiency....
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in the Phase II clinical trial evaluating its internally developed innovative drug candidate, LNK01004 ointment, for the treatment of...
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO, July 9, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACROBiosystems, the summit was uniquely designed as an international roadshow and licensing matchmaking platform dedicated...
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company presented its latest advances in AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody development platform at Booth...
Vermon launches Vermon Group, accelerating its growth and expanding its offerings
Vermon Group opens a new chapter with the acquisition of Moduleus, the opening of TransducerWorks' new U.S. manufacturing facility, and the launch of a coordinated Group platform designed to move faster, deliver more, and stay close to customers. TOURS, France, July 8, 2026 /PRNewswire/ -- Vermon Group, an international ultrasound technology...
Altruist Biologics’ Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HANGZHOU, China, July 8, 2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development...
Global Care Economy Set to Create Significant Growth Opportunities as Care-Dependent Population Reaches up to 4.6 Billion by 2035
Rapid population ageing and care worker shortages are accelerating demand for next-generation care infrastructure, AgeTech, and integrated care ecosystems LONDON, July 8, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, The Global Care Economy, Transformations and Opportunities to 2035, reveals that demographic change, mounting healthcare workforce shortages, and accelerating digital innovation are reshaping the global care economy and...
Seegene Launches Industry’s First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-informed clinical decision-making. The company is recognized as...
